in this study we report that the resistance to doxorubicin , an anthracycline antibiotic and the most active agent in the treatment of breast cancer , can be partially reversed by exposing mcf-7 doxorubicin-resistant breast tumor cells ( mcf-7/adrr ) to minimally cytotoxic doses of bso .
C0013089
doxorubicin
C1458155
breast